https://www.selleckchem.com/products/vit-2763.html
Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes. We analyzed retrospective data from the Pediatric PSC Consortium. Children treated with OVT were matched 111 to those treated with UDCA or managed with observation (no treatment) based on the closest propensity score, ensuring similar baseline characteristics. Two hundred sixty-four patients (88 each with OVT, UDCA, or observation) had mat
Like
Comment
Share
